Cassidy Henegar

Dr. Cassidy Henegar


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in AIDS Research and Human Retroviruses
Verified
Journal Article
Open access
KMKaram Mounzer
Karam Mounzer
LBLaurence Brunet
Laurence Brunet
RHRicky Hsu
Ricky Hsu
JFJennifer S Fusco
Jennifer S Fusco
VVVani Vannappagari
Vani Vannappagari
GFGregory P Fusco
Gregory P Fusco
With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess the association between ART regimens and changes in body mass index (BMI) among ART-experienced, virologically suppressed PLWH. ART-experienced, virologically suppressed PLWH ≥18 years of age in the Observational Pharmacoepidemiology Research and Analysis (OPERA) cohort were included for analysis if prescribed a new regimen containing one of the following core agents: dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), raltegravir (RAL), rilpivirine (RPV), or boosted darunavir (bDRV), for the first time between August 1, 2013 and December 31, 2017. Multivariable linear regression was used to assess the association between regimen and mean changes in BMI at 6, 12, and 24 months after switch. In unadjusted analyses, BMI increases ranged from 0.30 kg/m 2 (bDRV) to 0.83 kg/m 2 (RPV) at 24 months following switch, but gains were observed with every regimen. In adjusted analyses, compared to DTG, only bDRV was associated with a smaller increase in BMI at all time points, while EVG/c and RAL were associated with smaller increases in BMI at 6 months only. Overall, results were consistent in analyses stratified by baseline BMI category. BMI increases were relatively small but followed an upward trend over time in this cohort of treatment-experienced, suppressed PLWH. Gains were attenuated with a longer period of follow-up. BMI gains did not differ by regimens, except for bDRV regimens, which were consistently associated with smaller BMI increases than DTG.

14 December 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CHCassidy Henegar
Cassidy Henegar
ELEmilio Letang
Emilio Letang
RWRuolan Wang
Ruolan Wang
CHCharles Hicks
Charles Hicks
DFDainielle Fox
Dainielle Fox
VVVani Vannappagari
Vani Vannappagari
After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with HIV who experience virologic failure while on DTG-based regimens. We searched the PubMed, Embase, and Cochrane databases to identify studies that reported DTG resistance-associated mutations (RAMs) emerging under selection pressure. Our review showed that RAMs conferring resistance to DTG were rare in 2-drug and 3-drug regimens used in real-world cohorts, corroborating data from clinical trials. The potency of DTG in maintaining virologic suppression was demonstrated, even in cases of pre-existing resistance to companion drugs in the regimen. Estimates of DTG RAMs depended on the population and certain risk factors, including monotherapy, baseline resistance or lack of genotypic testing, treatment history and prior virologic failure, and suboptimal treatment adherence. The RAMs detected after virologic failure, often in heavily treatment-experienced individuals with prior exposure to integrase strand transfer inhibitors, were G118R, E138K, G140A/C/R/S, Q148H/K/R, N155H, and R263K. Overall, these data highlight the durable effectiveness and high barrier to resistance of DTG as part of combination antiretroviral therapy in a wide variety of settings.

7 January 2026 in HIV Medicine
Verified
Journal Article
Open access
CMCristina Mussini
Cristina Mussini
CHCassidy Henegar
Cassidy Henegar
LALambert Assoumou
Lambert Assoumou
SWStephane de Wit
Stephane de Wit
MJMargaret Johnson
Margaret Johnson
VVVani Vannappagari
Vani Vannappagari
Objectives: This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor ( INSTI ), and reverse transcriptase inhibitor ( RTI ), among suppressed people living with HIV in Europe. Methods: This observational cohort enrolled adults with HIV from 28 sites across Europe who were switching to a two‐drug regimen of an INSTI plus a nucleoside reverse transcriptase inhibitor or non‐nucleoside reverse transcriptase inhibitor while suppressed [viral load ( VL ) <50 copies/ mL ]. Participants were followed from regimen start date (baseline) until the earliest of 96 weeks, regimen discontinuation, loss to follow‐up, or death. The primary endpoints were suppression, low‐level viraemia ( VL ≥50 to <200 copies/ mL ), and high‐level viraemia ( VL ≥200 copies/ mL ) at 24‐, 48‐ and 96‐weeks post‐baseline, and virologic failure ( VF ) within 96 weeks (2 consecutive VLs ≥50 copies/ mL or 1 VL ≥50 copies/ mL followed by regimen discontinuation). Adverse events and discontinuations were also described. Results: 737 individuals switched to DTG + 3TC (536, 72.7%), DTG + RPV (186, 25.2%) and other INSTI+RTI regimens (15, 2.0%). At 24‐,48‐, and 96 weeks of follow up, >98% of individuals with VL data maintained suppression; among VLs ≥50 copies/mL, most (19/23; 82.6%) were low‐level viraemia. Five individuals (<1%, DTG + 3TC:2; DTG + RPV:3) experienced VF. Forty‐seven non‐serious drug‐related AEs were reported by 38 participants (5.4%); 2 people experienced serious AEs (0.3%). Regimen discontinuations were infrequent ( n = 39, 5.3%) and most commonly attributed to tolerability issues ( n = 17). Conclusions: Among suppressed people living with HIV in a real‐world setting, INSTI + RTI two‐drug regimens were highly effective and well tolerated over 96 weeks of follow‐up.